RxDoctor Payments Data

Jeffrey Danzis, DO

Family Medicine · New Britain, PANPI 1942232244

Payments from drug & device makers

$1,193in general payments, 2019–2025

Across 66 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$231
  • Novo Nordisk$170
  • AstraZeneca$159
  • Pfizer$94
  • Lilly USA, LLC$88
  • AbbVie$67
  • plus $383 from 15 others

What the payments were for

  • Food & beverage$1,193100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,193 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$21,645
Medicare patients
170
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin14$16,431
EliquisApixaban13$14,130
Rosuvastatin Calcium122$1,531
Atomoxetine Hcl13$1,212
Atorvastatin Calcium88$1,082
Desmopressin Acetate13$973
Albuterol Sulfate HfaAlbuterol Sulfate22$693
Tamsulosin Hcl51$684
Lisinopril90$552
Levothyroxine Sodium69$504
Losartan Potassium25$490
Metoprolol Succinate36$371
Amlodipine Besylate53$371
Metformin Hcl64$359
Gabapentin11$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$14,13013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in New Britain

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →